GCG and Alzheimer disease: GLP-1 has demonstrated efficacy in clinical trials in patients with AD [157, 158]; however, GLP-1 undergoes easy degradation, and therefore, continuous intravenous infusions or continuous subcutaneous injections are necessary to perform therapeutic roles, thus limiting its clinical application [154].